Monday, March 25, 2013
LDL-P should be considered as a primary goal of therapy due to its stronger association with cardiovascular risk.
Historically, clinicians manage a patient's risk for cardiovascular disease by measuring plasma lipids such as LDL-C, HDL-C and triglycerides. More recently, it's been shown that measurement of lipoprotein particles, the containers that carry cholesterol, may be beneficial for patient management.
Among cardiometabolic risk (CMR) patients, about two-thirds have high Low Density Lipoprotein particle number (LDL-P) despite optimal levels of LDL-C. For cardiometabolic risk patients, LDL-P should be considered as a primary goal of therapy due to its stronger association with cardiovascular risk.1
Manage your patients with clarity and confidence with LDL-P by NMR.
1. Rosenson et al. Atherosclerosis. 2010; 213:1-7
Read the full article here.